Identification of an AVP-NPII mutation within the AVP moiety in a family with neurohypophyseal diabetes insipidus: review of the literature

Costas Koufaris,1 Angelos Alexandrou,1 Carolina Sismani,1 Nicos Skordis2

1Department of Cytogenetics and Genomics, Cyprus Institute of Neurology and Genetics; 2Division of Pediatric Endocrinology, Paedi Center for Specialized Pediatrics; Nicosia, Cyprus

ABSTRACT

Familial neurohypophyseal diabetes insipidus (FNDI) is a disorder characterized by excess excretion of diluted urine (polyuria) and increased uptake of fluids (polydipsia). The disorder is caused by mutations affecting the AVP-NPII gene, resulting in absent or deficient secretion of the antidiuretic hormone arginine vasopressin (AVP) by the neurohypophysis. In this study we examined a three-generation Cypriot kindred suspected to have FNDI. Direct sequencing analysis of AVP-NPII identified a missense mutation (NM_000490.4:c.61T>C; p.Tyr21His; rs121964893) within the AVP moiety on exon 1 of the gene in all affected family members. So far, only three studies have reported mutations within the AVP moiety of AVP-NPII as being associated with FNDI, with the vast majority of identified FNDI mutations being located within the signalling peptide or the neurophysin II (NPII) moiety of the gene. The mutation within the AVP moiety identified here had been reported previously in a Turkish kindred with FNDI. Consequently, the findings of this study confirm the causal role of mutations within the AVP moiety in FNDI. Herein we review reported mutations within the AVP moiety of AVP-NPII and their contribution to FNDI.

Key words: Arginine vasopressin, Autosomal dominant, Founder mutation, Mutation, Neurohypophyseal diabetes insipidus, Sanger sequencing

INTRODUCTION

Diabetes insipidus (DI) is a disorder of water balance, characterized by the excretion of copious amounts of urine and the compensatory consumption of very large quantities of fluids, which can be life-threatening if not managed properly. DI is a rare disease with a nonunivocal reported prevalence of 1:25,000.1 DI can be acquired as a result of hypothalamic injury or can also be the result of mutations affecting the vasopressin-neurophysin II precursor (AVP-NPII) gene, the AVP receptor 2 (AVPR2) or the aquaporin 2 (AQ2) water channel protein.2

Familial neurohypophyseal diabetes insipidus (FNDI) is caused by mutations affecting the AVP-NPII gene resulting in the absence or deficiency of the
anti-diuretic hormone (ADH). This hormone acts to regulate the retention of water through increased water reabsorption in the collecting ducts of the nephron.3

The AVP-NPII gene is an autosomal gene located at 20p13 and is composed of three exons and two introns (Figure 1A). The 19 amino acid long sequence of the signal peptide and the 9 amino acid long sequence of the AVP moiety are encoded within the first exon. The 93 amino acid long N-terminal of the neurophysin II (NPII) is coded across all three exons, with exon 2 coding for the conserved core of NPII and the C-terminal encoded within exon 3. The 39 amino acid glycopeptide known as copeptin is also encoded within exon 3.3 The AVP-NPII product, the AVP preprohormone, is produced in the hypothalamus and is targeted to the endoplasmic reticulum (ER) by the signal peptide. Within the ER the signal peptide is removed and the copeptide is glycosylated. After cleavage and processing, the AVP hormone and its protein carrier NPII are transported to the nearby neurophysin where they can be stored and secreted when necessary to act on the kidney.

In the majority of cases FNDI is inherited in a completely penetrant, autosomal dominant manner.3 Currently, more than 60 mutations affecting AVP-NPII have been associated with FNDI.1,4 The great majority of FNDI mutations are located within the signal peptide or the NPII moiety of the AVP-NPII gene.3,5-7 However, a few cases have been identified of FNDI caused by mutations within the AVP moiety.8,10

In this study, a three-generation Cypriot family with suspected FNDI was investigated by direct sequence of all three AVP-NPII exons to identify potential pathogenic mutations. A single mutation was identified in affected members of this family within the AVP moiety in exon 2 of the AVP-NPII gene.

MATERIALS AND METHODS

Patients

Five affected members of three-generation FNDI kindred were studied. The pedigree (Figure 2A) is consistent with an autosomal dominant mode of transmission. All members had had polyuria and polydipsia since early childhood but received treatment with desmopressin (DDA VP) relatively late. The proband (patient 2) is an 8-year old boy who had presented with polyuria and polydipsia since infancy. The patient underwent a water deprivation test, which lasted 4 hours and terminated when 25 mcg of DDAVP was administered intranasally that confirmed the diagnosis of central DI. During the test the plasma osmolality increased from 282 to 294 mosm/kg, while the urine osmolality remained low at 150 mosm/kg but increased to 650 mosm/kg following administration of DDAVP. Patient 4, having been symptomatic since infancy, was initially seen at age 17 years. Although the diagnosis was obvious based on the family history, he underwent the water deprivation test which confirmed the diagnosis and an MRI of the pituitary which did not reveal the characteristic bright spot of the posterior pituitary lobe on T1 – weighted images. All patients are in excellent health and doing well on treatment with DDAVP.

DNA extraction

DNA was extracted using the Qiagen DNA extraction kit (Qiagen Co) according to the manufacturer’s recommendations. The DNA was subsequently quantified using a Nanodrop ND-1000 spectrophotometer.

Sanger sequencing

Primers specific for the three exons of AVP were designed using the Primer3 software.11 The sequence of the primers used for Sanger sequencing of the AVP gene are available upon request. Amplification of the
exonic sequences of \textit{AVP} was performed by PCR using 10ng of genomic DNA and the AmpliTaq polymerase (Invitrogen). PCR products were subjected to gel electrophoresis to ensure the absence of non-specific bands. Purification of PCR products was performed using Exo-Sap\textsuperscript{11} (Affymetrix). Sequencing reactions were performed using Applied Biosystems BigDye terminator v1.1 (Life Technologies) following the manufacturer’s instructions and products were analyzed on an ABI 3130 sequencer. The DNA sequences of the PCR products were mapped to the reference genome using BLAT\textsuperscript{12} to determine the presence of inherited variants.

**RESULTS**

**Genetic studies**

Sanger sequencing of the three exons of the \textit{AVP} gene identified a single variant that was present in all four affected DI patients, a missense variant it prehormone and position 2 of the mature \textit{AVP} (NM_000490.4:c.61T>C; p.Tyr21His; rs121964893) (Figure 2B).

**DISCUSSION**

All the affected kindred discussed herein were found to carry a missense mutation resulting in the substitution of histidine for tyrosine at position 2 of \textit{AVP}. The same mutation had been previously reported to co-segregate with the disease in a three-generation Turkish kindred with FNDI.\textsuperscript{9} In those patients, the mutation was associated clinically with inability to concentrate urine during fluid deprivation, a greater than 80% deficiency of \textit{AVP} secretion and absence of the posterior pituitary bright spot on magnetic resonance imaging. Christensen et al,\textsuperscript{7} using \textit{in vitro} models, showed that this mutation retarded the processing of the AVP-NPII prehormone and its accumulation in the endoplasmic reticulum causing reduced secretion. Consequently, this study confirms the causal role of missense mutations affecting this amino acid in the development of FNDI.

The ability of \textit{AVP-NPII} mutations to cause autosomal dominant FNDI has been proposed as occurring through two mechanisms.\textsuperscript{1,3} The first mechanism involves the accumulation of the AVP prehormone in the ER of cells, followed by cell dysfunction and death. Autopsies have found loss of AVP-secreting cells in DI patients.\textsuperscript{13,14} In a mouse model of FNDI, the presence of a truncated version of vasopressin was associated with progressive loss of AVP-producing neurons.\textsuperscript{15} In a recent publication, evidence has been reported that in an FNDI mouse model, loss of AVP-secreting neurons occurs due to autophagy induced by ER stress.\textsuperscript{16} A second mechanism involves the

![Figure 2](image_url)

*Figure 2.* Identification of pathogenic mutation within exon 1 of the \textit{AVP-NPII} in Cypriot kindred with FNDI. (A) Pedigree of Cypriot family with familial DI. Family members with historical or laboratory evidence for DI are indicated with filled symbols; (B) sequencing chromatogram from a fragment of exon 1 of the \textit{AVP-NPII} containing identified variant is shown for four examined patients. Arrow shows the location of the missense mutation.
A VP-NPII mutation associated with FNDI

445
direct interaction between the mutant A VP-NPII and the wildtype precursors which blocks its processing in a dominant negative manner. It has been shown in cell models that mutant AVP precursors can form heterodimers with their wildtype counterparts and block their secretion. A study has also reported the development of progressive polyuria in a mouse model of FNDI without the loss of vasopressin neurons. It is therefore conceivable that loss of A VP-secreting neurons is a nonessential part of FNDI development.

Autosomal dominant FNDI mutations, whether acting by inducing neuronal loss or through interaction of wildtype-mutant A VP precursors, operate by disrupting the physiological folding and processing of A VP-NPII. The majority of these mutations are located within the signalling peptide or in the NPII moiety. For example, Rittig et al examined 17 unrelated kindred with FNDI. The researchers identified 13 novel A VP-NPII mutations of which 2 were missense mutations within the signalling peptide, 8 mutations in the NPII moiety in exon 2 and 3 nonsense mutations in the NPII moiety in exon 3. Similarly, Christensen et al screened the A VP-NPII gene for mutations in 15 unrelated kindred. This study found 2 novel mutations in the signalling peptide and 4 novel mutations within the NPII moiety. This pattern of the majority of mutations in FNDI located in the NPII moiety followed by the signalling peptide of the A VP precursor has been consistent in a large number of unrelated FNDI kindred studies since then.

Nevertheless, studies have found a few cases of autosomal dominant mutations associated with FNDI affecting specifically positions 2 and 3 of AVP (Figure 1B). Rittig et al found the same missense mutation identified in the present study in Turkish kindred with FNDI. Wahlstrom et al reported a 3-base pair deletion resulting in loss of phenylalanine at position 3 of the AVP hormone in an American FNDI kindred. Kobayashi et al reported a missense substitution at position 2 of AVP of tyrosine by serine in a Japanese patient, the same position found to be affected by Rittig et al and by this study, although involving a distinct amino acid substitution.

Crystallography and biochemical data suggest that the dimerisation of NPII with AVP occurs between the first 3 N-terminal amino acids of the hormone and pockets formed by several amino acid residues of NPII. It has been proposed that the rarity of mutations within the AVP moiety associated with FNDI relate to the fact that only the first 3 N-terminal amino acids of AVP are essential for the proper processing and folding of the prehormone. Another interesting case involved a missense mutation that predicts for a substitution of leucine for proline at position 7 of AVP. However, in this case the mutation was considered to be associated with autosomal recessive FNDI, thus it does not possess dominant negative effects and is probably pathogenic due to the loss of the normal functioning protein.

Given the geographic and historical links between the Cypriots and Turkish and other Middle Eastern populations it is difficult to exclude the likelihood that the identical missense mutation identified in this study to the one reported by Rittig can be traced back to the same ancestor, i.e. it concerns a founder effect. A large fraction of hereditary endocrinopathies in Cyprus have been associated with founder effects involving previous migrations to the island, in ancient times of Phoenician populations and more recently of people of Turkish, Arab and other ancestries which have shaped the Cypriot gene pool. Identical splice-mutations affecting the 5alpha-steroid reductase type 2 gene (SRD5A2) gene—5aSRD IVS1-2A>G—have been found in Cypriots which are most probably due to a founder effect.

In conclusion, we report here a Cypriot family with FNDI associated with a mutation within the AVP moiety of the A VP-NPII gene. This offers further confirmation that mutations affecting position 2 of AVP are causally implicated in autosomal dominant FNDI.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent

The informed consent was obtained from all individual participants included in the study.

REFERENCES